12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
نویسندگان
چکیده
منابع مشابه
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
BACKGROUND Highly effective hepatitis C virus (HCV) direct-acting antiviral therapies that do not require modification of human immunodeficiency virus (HIV) antiretroviral regimens are needed. We evaluated the efficacy and safety of daclatasvir + sofosbuvir (DCV + SOF) for 12 weeks by antiretroviral (ARV) regimen in HIV-HCV-coinfected patients. METHODS In the randomized, open-label ALLY-2 stu...
متن کاملDaclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.
BACKGROUND: All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3. METHODS: In this open-label study, we initially randomly assigned 44 previously untreated pa...
متن کامل820Triple Combination Treatment With Peginterferon Lambda-1a, Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b
Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b Maurizia Brunetto, MD; Khurram Rana; Gloria Taliani; Eric Lawitz; Christophe Hézode; Patrick Marcellin; Lawrence Serfaty; David Cohen; Subasree Srinivasan; Liver Unit University Hospital of Pisa, Pisa, Italy; BristolMyers Squibb, Wallingford, CT; Azienda Ospedaliera Universitaria, Policlinico Umberto I, Roma, Italy...
متن کاملSofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.
Recurrent HCV infection following liver transplantation can lead to accelerated allograft injury that is difficult to treat with interferon. The aim of this study is to describe the first ever use of an interferon-free, all oral regimen in a liver transplant recipient with severe recurrent HCV. A 54-year-old male with HCV genotype 1b developed severe cholestatic HCV at 6 months posttransplant w...
متن کاملSafety and efficacy of daclatasvir in the management of patients with chronic hepatitis C
Daclatasvir (Daklinza™), a new oral direct-acting antiviral, is an inhibitor of hepatitis C virus NS5A protein and has recently been approved in the United States, Europe and Japan in chronic hepatitis C. It shows potent pangenotypic activity and moderately high genetic barrier to resistance improving the sustained virological response (SVR) rates. In COMMAND phase 2 trials, daclatasvir demonst...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Open Forum Infectious Diseases
سال: 2015
ISSN: 2328-8957
DOI: 10.1093/ofid/ofv133.1223